Company Description
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137.
In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas.
It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 2009 |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 305 |
| CEO | Kevin Lee |
Contact Details
Address: Portway Building, Blocks A & B Cambridge, CB21 6GS United Kingdom | |
| Phone | 44 1223 261 503 |
| Website | bicycletherapeutics.com |
Stock Details
| Ticker Symbol | BCYC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001761612 |
| CUSIP Number | 088786108 |
| ISIN Number | US0887861088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | Chief Executive Officer and Executive Director |
| Alethia Rene Young | Chief Financial Officer |
| Alistair Milnes | Chief Operating Officer |
| Prof. Michael Charles-Ferguson Hannay | Chief Product and Supply Chain Officer |
| Dr. Christian Heinis | Scientific Founder |
| Travis Thompson | Senior Vice President, Chief Accounting Officer and Principal Accounting Officer |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer |
| Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications |
| Zafar Qadir | Chief Legal Officer and General Counsel |
| Dr. Gillian Langford | Head of Clinical and Project Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2025 | 144 | Filing |
| Jul 2, 2025 | 144 | Filing |
| Jul 2, 2025 | 144 | Filing |
| Jul 2, 2025 | 144 | Filing |
| Jul 2, 2025 | 144 | Filing |
| Jul 2, 2025 | 144 | Filing |
| Jun 17, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |